congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
A phase 1b/2 open-label study evaluating trastuzumab deruxtecan in combination with rilvegostomig and chemotherapy in patients with HER2-positive and HER2-low gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03
Part 4
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
A retrospective study to investigate the prevalence and treatment outcomes of HER2-low unresectable/metastatic breast cancer in Taiwan — the RetroBC-HER2L-TW study
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Clinical characteristics of patients with HER2+ unresectable or metastatic breast cancer: HER2 REAL Asia cohort
Mini-Oral
Dato-DXd
ESMO Asia 2024 | December 6-8, 2024
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with pre-treated inoperable/metastatic HR+/HER2– breast cancer: Results from TROPION-Breast01 China cohort
Oral
Dato-DXd
ESMO Asia 2024 | December 6-8, 2024
Efficacy and safety of datopotamab deruxtecan in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): pooled analysis of TROPION-Lung01 and TROPION-Lung05
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Randomized, open-label, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Real-world treatment patterns and survival outcomes in patients with HER2+ unresectable or metastatic breast cancer: HER2 REAL Asia cohort
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Real-world treatment patterns in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+ aGC/GEJC) in East Asia (HER2+ GASTA)
Mini-Oral
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis